BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Clinical trials for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) explained in plain language.
Never miss a new study
Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) trials appear
Sign up with your email to follow new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets rare blood cancer in early trial
Disease control Recruiting nowThis study tests a two-drug combination (tagraxofusp and venetoclax) in adults with a rare and aggressive blood cancer called BPDCN who have not had prior treatment. The main goal is to see if the combination can achieve complete remission after 3 months. Depending on results, pa…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Experimental CART123 therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called CART123 for people with certain blood cancers (like AML or MDS) that have not responded to standard treatments. Each patient's own immune cells are modified in a lab to recognize and attack cancer cells. The main goa…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Rare cancer registry aims to unlock treatment secrets
Knowledge-focused Recruiting nowThis study creates a worldwide registry for people diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare blood cancer. Researchers will collect information on how the disease presents, how it is treated, and what happens to patients over time. The goal …
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Immune Oncology Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC